In preparation for the 55th ERA-EDTA congress this week in Copenhagen, the COMPACT RENAL team has produced a summary of the key presentations and posters related to iron deficiency and anaemia.
The team have also been preparing for the new e-campus for this year’s congress which will showcase the educational materials available on COMPACT RENAL, alongside features such as a rare conditions corner, dedicated learning stations, internet access and, perhaps most importantly, refreshments.
For more information on the topics covered at the e-campus see our news article. We look forward to seeing you at the e-campus in between the selection of iron deficiency/anaemia talks outlined below.
Friday, May 25th
The sessions relevant to iron deficiency and anaemia begin on Friday with a late-breaking presentation of data from a trial of ferric citrate in advanced chronic kidney disease by the study chair, Geoffrey Block, USA.
Two posters of relevance report data for ferric pyrophosphate citrate (FPC). Poster FP753 looks at the pharmacokinetics of FPC in a paediatric haemodialysis population, where FPC was delivered either with dialysis or intravenously. FP475 compares the pharmacokinetics of FPC delivered via peritoneal dialysis or intravenously.
Saturday, May 26th
The “Anaemia in CKD” session on Saturday morning, chaired by Iain C Macdougall, UK and Yalcin Solak, Turkey, starts with a mini-lecture on the role of inflammation in renal anaemia followed by several free communication presentations; including:
- Results of two studies on the ocular safety of the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI),daprodustat [SAO004]
- The NIMO UK observational study of the efficacy of iron isomaltoside in pre-dialysis patients with anaemia [SAO001]
- Pooled analysis of three studies of iron isomaltoside in both pre-dialysis and haemodialysis patients [SAO002]
The lunchtime Educational Symposia supported by AstraZeneca invites attendees to meet ‘Mr Andersen’. The session will include presentations by Professors Biff Palmer,USA, Roberto Pecoits-Filho, Brazil and Iain Macdougall, UK on the significance of hyperkalaemia and renal anaemia, and how they would approach the management of these issues, not only for Mr Andersen, but in all patients.
The Free Communication session, ‘CKD-MBD’, contains a talk on a pilot study of the effect of ferric carboxymaltose on intact FGF23 levels. [SaO029]
Posters of interest on Saturday include:
- A DOPPS-derived study examining the association between low hemoglobin levels at dialysis initiation and survival in the first year after dialysis start [SP340]
- Two presentations on HIF-PHIs, molidustat [SP334] and a pharmacology study of the novel agent, TP0463518 [SP331]
- Poster SP333 examines the association of quality-of-life scores with kidney disease stage and haemoglobin levels, while SP338 highlights a systematic review of the use of ESAs and associated costs and health-related quality-of-life.
- A team from Japan will present poster SP339, a study to identify the factors associated with an initial hyporesponsiveness to treatment with darbopoetin in non-dialysis patients.
Sunday, May 27th
The highlight of Sunday will be a Symposia chaired by Iain C Macdougall, UK and Kai-Uwe Eckardt, Germany, entitled “New methods of anaemia management in CKD patients”. The session will cover new and existing options for the management of haemoglobin levels in chronic kidney disease, with the following presentations:
- PHIs – safety and efficacy – results from recent clinical trials. David Wheeler, UK
- Iron supplementation in CKD patients – what is the optimal dose and optimal route of administration in 2018? Iain C Macdougall, UK
- Mechanisms of hypertension induced by erythropoietin and related agents. Michal Nowicki, Poland
- What is the future of rHuEPO? Francesco Locatelli, Italy
We wish you a safe journey to Copenhagen, and look forward to reporting back on all the key presentations here at COMPACT-RENAL.com.